In summary, the study results study suggest that there is no statistically significant difference in OS, PFS, and grade ≥ 3 TRAEs with PD-1 + Chemo or PD-L1 + Chemo for first-line treatment in patients with ES-SCLC. The gene discussed is PDCD1; the disease is small cell lung carcinoma.